European Medicines Agency (EMA) receives application for conditional marketing authorisation of Moderna COVID-19 vaccine

Assessment of the COVID-19 mRNA vaccine by Moderna Biotech Spain, S.L. BNT162b2 will proceed under an accelerated timeline; and an opinion on the marketing authorisation could be issued within weeks, depending on quality, safety and effectiveness data.

Source:

European Medicines Agency